Meeting
2020 ASCO Virtual Scientific Program
Phase III study of the hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 versus everolimus in previously treated patients with advanced clear cell renal cell carcinoma (ccRCC).
Authors
Toni K. Choueiri
Dana-Farber Cancer Institute, Boston, MA
Toni K. Choueiri , Laurence Albiges , Li Fan , Rodolfo F. Perini , Naseem J. Zojwalla , Thomas Powles , Brian I. Rini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT04195750
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS5094)
DOI
10.1200/JCO.2020.38.15_suppl.TPS5094
Abstract #
TPS5094
Poster Bd #
163
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
MK-6482, a hypoxia-inducible factor 2α inhibitor (HIF-2α), versus everolimus in heavily pretreated, immune checkpoint–inhibitor-resistant, advanced clear cell renal cell carcinoma (ccRCC): Phase III study.
First Author: Toni K. Choueiri
Poster
2020 Genitourinary Cancers Symposium
Phase II study of the oral hypoxia-inducible factor 2α (HIF-2 α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).
First Author: Scott S. Tykodi
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC).
First Author: Toni K. Choueiri
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced clear cell renal cell carcinoma (ccRCC).
First Author: Robert J. Motzer